Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10485771

    Methods of regulating cannabinoid receptor activity-related disorders and diseases

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10485959

    Drug releasing coatings for balloon catheters

    Lutonix, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10485796

    LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

    Biomed Valley Discoveries, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10487054

    Therapeutic compounds

    Regents of the University of Minnesota · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10485774

    Enterically coated cysteamine, cystamine and derivatives thereof

    The Regents of the University of California · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10485782

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10487140

    Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10485766

    Drug delivery system and method for the treatment of neuro-degenerative disease

    Aphios Corporation · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10487105

    Trinucleotide MRNA cap analogs

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10485792

    Sustained release delivery systems for the prevention and treatment of head and neck cancers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10485829

    Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

    Astellas Institute for Regenerative Medicine · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10485850

    Methods for producing stable therapeutic formulations in aprotic polar solvents

    XERIS PHARMACEUTICALS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10485879

    Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues

    Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10485958

    Drug releasing coatings for balloon catheters

    Lutonix, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10487076

    Compositions and methods for treating diseases and conditions

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10487088

    Tricyclic compound serving as immunomodulator

    Medshine Discovery Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10488416

    Targeting breast cancer therapy based on stromal subtypes and CD146 composition

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10488417

    Compounds for use as imaging agents

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10485809

    Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10485841

    Method for producing dry extracts

    BIONORICA SE · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10485869

    Etanercept formulations stabilized with meglumine

    Coherus BioSciences, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10485871

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10485844

    Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10485877

    Oligomer-phenothiazine conjugates

    Nektar Therapeutics · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10487341

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. WO 2019224246

    MÉTHODES FONDÉES SUR DES BIOMARQUEURS DESTINÉES AU TRAITEMENT D'UNE MALADIE ATOPIQUE PAR IMMUNOTHÉRAPIE

    ALK ABELLO AS [DK] · Granted Thu Nov 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Nov 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10493087

    Sialylation-increasing therapies for diseases associated with oxidative stress

    The United States of America, as represented by National Institute of Health · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10494648

    Delivery methods and compositions for nuclease-mediated genome engineering

    Sangamo Therapeutics, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10494440

    Use of semaphorin-4D binding molecules to promote neurogenesis following stroke

    VACCINEX, INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10494619

    High isomerohydrolase activity mutants of human RPE65

    The Board of Regents of the University of Oklahoma · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10494405

    Methods and compositions for the treatment of arthritis

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10494401

    LLP2A-bisphosphonate conjugates for osteoporosis treatment

    The Regents of the University of California · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10494402

    Peptides that stimulate subcutaneous adipogenesis

    The Regents of the University of California · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10494382

    Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and water

    Theravance Biopharma R&D IP, LLC · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10494347

    Processes for the preparation of uracil derivatives

    Neurocrine Biosciences, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10494683

    Nitrate- and nitrite-reducing probiotic feed additive

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10494316

    Process for the preparation of deuterated ethanol from D2O

    Deuteria Beverages, LLC · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10493162

    Somatostatin receptor-based cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10493151

    Etanercept formulations stabilized with sodium chloride

    Coherus BioSciences, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10493149

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10493092

    Antisense compounds

    Ionis Pharmaceuticals, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10493098

    Mesoporous silica-coated nanoparticles

    Regents of the University of Minnesota · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10493103

    Peroxide formulations and methods and applicators for using the same

    Aclaris Therapeutics, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10493065

    Formulations and methods of manufacturing formulations for use in colonic evacuation

    RedHill Biopharma Ltd. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10493069

    Methods of treating behavioral syndromes using pipradrol

    OVID THERAPEUTICS INC. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10493066

    Fumarate analogs and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10493057

    Acetogenin molecules having antiplatelet and/or antithrombic activities, and methods and compositions thereof

    INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10493037

    Multiphasic particles fabricated by wettability engendered templated self-assembly (WETS) methods

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.